XTAE
TKUN-M
Market cap38mUSD
Sep 09, Last price
6,830,000.00ILS
Name
Tikun Olam Cannbit Pharmaceuticals Ltd
Chart & performance
P/E
—
P/S
12.75
EPS
—
Div yield, %
—
Shrs. gr., 5y
-65.82%
Rev. gr., 5y
-15.92%
Revenues
9m
-73.96%
Net income
-16m
L-60.47%
CFO
618k
P
Dividend
Dec 28, 20110.300583 ILS/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Tikun Olam-Cannbit Pharmaceuticals Ltd engages in the cultivation, production, marketing, storage, distribution, export and import, and sale of cannabis-based products in Israel. The company provides medical cannabis products for the treatment and relief of symptoms in a wide variety of medical indications. It also offers clinical research, training, and patient care services. Tikun Olam-Cannbit Pharmaceuticals Ltd was founded in 2006 and is based in Nof HaGalil, Israel.
Key people
Ifat Kariv
Chief Executive Officer, Director · since 2019
Vice President - Finance · since 2017
Internal Auditor · since 2017
Eli Admoni
Director · since 2019
Eitan Ben-Eliahu
Chairman of the Board · since 2019
Dan Engel Potashkin
Director · since 2019
Daniel Gimpel
Director · since 2014
Yaron Naor
Director · since 2019
Erez Navon
Director · since 2019
Yaron Razon
Director · since 2019
Aminadav Sessler
Director · since 2019
External Director · since 2009
External Director · since 2015
External Director · since 2010
External Director · since 2015
Isaac Ashkenazi
Independent Director · since 2019
Headquarters & legal address
אלון 83
שדה אליעזר, Z 1220500
IL
שדה אליעזר, Z 1220500
IL
Trading name
TIKUN OLAM LTD
Valuation
Title ILS in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||